CDMRP

Dear Research Advocate: Big news: it appears a Labor-H/Defense appropriations “conference report” (i.e. final bill) will clear Congress and reach the President’s desk before the September 30 deadline. Earlier this week, we sent a letter urging conferees Senator Roy Blunt (R-MO), Senator Patty Murray (D-WA), Representative Tom Cole (R-OK), and Representative Rosa DeLauro (D-CT) to push for the highest funding levels possible for NIH, CDC, AHRQ and CDMRP given the boundaries set by the House and Senate versions of the legislation. This just in: a summary of the conference report . A preliminary read (emphasis on “preliminary”) indicates that the conferees did indeed opt for favorable funding...
Dear Research Advocate: President Trump signed the John S. McCain National Defense Authorization Act for Fiscal Year 2019 (NDAA), authorizing $716 billion in spending for the Department of Defense (DoD). R&D features prominently, including the Congressionally Directed Medical Research Program ( CDMRP ), the WRAIR Labs, and other medical and public health research pivotal to domestic and global health security. A particularly compelling example of the value of defense research is the recent story of the youngest person to receive a face transplant in U.S. history, part of a research study DoD funded because of its critical applications for wounded warriors. Read more in this USA Today...
Dear Research Advocate: The Senate approved a four-bill minibus package including appropriations under the jurisdiction of the Interior-Environment, Financial Services, Agriculture (which includes FDA) and Transportation-HUD Subcommittees yesterday, and will now likely take up a combined Labor-H/Defense appropriations bill (inclusive of NIH, CDC, AHRQ, the Department of Defense CDMRP and other important research funding). Research!America sent a letter to Appropriations leaders today reinforcing their commendable efforts to wrap up FY19 appropriations before the 9/30 deadline. The stakes here are high: the alternative scenarios -- either flat funding under a continuing resolution or a...
More than 250,000 Americans will be diagnosed with breast cancer this year, and 40,000 individuals will lose their lives to the disease (most to metastatic breast cancer, or MBC, which is breast cancer that has spread to other organs in the body). From Susan G. Komen’s point of view, investment in breakthrough breast cancer research, especially in projects focused on metastatic disease, is one of the most significant ways we can make progress and save lives from breast cancer. But research is expensive, and metastatic disease is cunning. An estimated 94% of women who are diagnosed with MBC were previously diagnosed with an earlier stage of the disease, maybe even decades prior. Then the...

Sidebar Quote

If concerted, long-term investments in research are not made, America will lose an entire generation of young scientists.
Brenda Canine, PhD; McLaughlin Research Institute, Montana